CV Tentori December 2015

EDUCATION
1980 Degree in Medicine *magna cum laude*
1983 Specialization in Hematology at the University of Rome "La Sapienza"

POSITION HELD AND SCIENTIFIC CAREER:

2015-present Associate Professor of Pharmacology, University of Rome "Tor Vergata"

2000-2015 Assistant Professor of Pharmacology, University of Rome "Tor Vergata"

1991-2000 Researcher, University of Rome "Tor Vergata"

1988-1991 Fellow, National Research Council (CNR), Rome

1986-1988 Visiting Fellow, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

1982-1986 Fellow, CNR

PUBLICATIONS
Co-author of 89 full papers in Medline-cited journals (first-last author in 41 papers). H Factor: 29; citations: 2272

RESEARCH ACTIVITY
2014-2016 Coordinator and Principal Investigator (PI) in the Research Project Uncovering Excellence funded by the University of Rome Tor Vergata, entitled "Implications of GDF11 and PARP1 in counteracting age-related decline by training"

2008-2010 PI in the Research Project of National Interest (PRIN) funded by the Italian Ministry of University Scientific Research (MIUR), entitled "Role of PARP and its pharmacological modulation in the resistance of colorectal cancer to antitumor drugs"

2009-2011 Coordinator and PI in the Educational Program of the Italian Ministry of Health on the drugs used to enhance athletic performance

2005-2007 PI in the PRIN project entitled "Role of PARP in tumor chemoresistance"

2003-2005 PI in the PRIN project entitled "Chemopotentiation and protection from toxicity by PARP inhibitors in cancer therapy"

2001-2008 PI in Research projects funded by the University of Rome "Tor Vergata"

1998; 2000-2003 Participant in research projects funded by MIUR, and by the Italian Association for Cancer Research

1997 PI in the Research Project funded by the CNR, entitled: "Therapeutic potential of the triazene compounds in the therapy of acute leukemia, role of apoptosis"

MAIN RESEARCH INTERESTS:
Study on the mechanisms involved in the cytotoxic activity of antitumor agents, resistance to anticancer drugs, pharmacological modulation of tumor chemoresistance through the use of poly(ADP-ribose)polymerase (PARP) inhibitors. Immunopharmacology.
Adverse effects of the drugs used to enhance sport performance. Educational programs to foster anti-doping behaviours

EXPERTISE
Preclinical in vitro and in vivo tumor models to select and evaluate pharmacological strategies aimed at overcoming chemoresistance such as new dosing schedules, combinatorial treatments with chemotherapeutic agents and with modulators of DNA repair systems

2007 to present Member of Ethical Animal Experimentation Committee, Interdepartmental Service Center, University of Rome “Tor Vergata”

TEACHING
Courses of pharmacology in Motor science degree; Physical activity and health promotion; in Sports Sciences and Techniques (Specialist degrees); Post-graduate School of Oncology, Faculty of Medicine; Post-graduate School of Dental Medicine University of Rome “Tor Vergata”; School of Dental Medicine, University of Tirana, Albania